Navigation Links
McLean Hospital researchers awarded $1.9 9 million grant for stem cell, blood research
Date:9/29/2010

Belmont, MAResearchers at Harvard-Affiliated McLean Hospital have been awarded a $1.9 million National Institutes of Health Director's Opportunity Award to continue their research into creating human induced pluripotent (iPS) stem cells using a method aimed at eliminating the risk of cancer and other problems associated with other options such as genome-integrating viral methods.

The three-year grant, made possible through the American Recovery and Reinvestment Act of 2009, was awarded to a research team headed by Kwang-Soo Kim, PhD, director of the Molecular Neurobiology Laboratory at McLean, and Robert Lanza at Stem Cell & Regenerative Medicine International (SCRMI), which is a joint venture with Advanced Cell Technology (ACT) of Worcester and CHA Biotech of Korea.

The joint venture involving ACT has been active in researching the use of these protein-induced pluripotent stem cells as a source of universal red blood cells and platelets for transfusion.

"This was really perfect timing for us because this work is a little bit beyond the capability of a single laboratory. It is technically demanding, labor intensive and expensive research," said Kim. "The award will support our continued research into iPS cell use that both avoids the risk of cancer growth and genetic dysfunction and provides a potential source of unlimited blood supply."

In 2009, Kim's team published an important study in the journal Cell Stem Cell, showing the ability to create stem cells out of human skin cells, eliminating the risk of cancer and removing some of the ethical concerns associated with embryonic stem cells. The paper described using proteins rather than genes or viruses to reprogram human skin cells, eliminating the risk of cancers or other abnormalities developing in the reprogrammed cells associated with the use of genes or viruses.

"The technique is hoped to result in the availability of the first clinic-ready human induced iPS cells, which could ultimately result in the development of treatments for a variety of illnesses, including Alzheimer's and Parkinson's," said Kim. "The technique of using a patient's own skin cells also eliminates the problem of immune rejection that is associated with using embryonic stem cells."

The researchers not only want to apply the technology for stem cell therapy but also for disease modeling, a process that would allow for their use in the laboratory to study disease mechanisms and in pharmaceutical companies to screen new medications.

"The ultimate goal is to use them in personalized cell therapy," explained Kim.

At the same time, the grant money will be used to see whether the iPS cells can be turned into blood lineage cells, including platelets. The SCRMI lab, headed by Lanza, has already shown the ability to make blood lineage cells from human embryonic stem cells.

If the same can be done from human iPS cells, it might be able to generate blood cells for certain patients so they can receive transfusions of blood and platelets from themselves, Kim said.

It would eliminate the problem of rejection and would provide blood lineage cells such as platelets that will be extremely useful in potentially life-threatening situations of blood shortages, he said.

A third goal of the research is to seek to make iPS cells from tissues of patients who have the rare universal blood types Rh- and O-, he added. "If we can make an unlimited amount of blood from these iPS cells, the blood could be used universally, particularly in crisis situations such as war," he said.

"Dr. Lanza's team has the world's top expertise in how to differentiate human embryonic stem cells or iPS cells to blood lineage cells," Kim said. "That is why they have combined with my lab, where we have the expertise to generate iPS cells using the protein method."


'/>"/>

Contact: Adriana Bobinchock
abobinchock@partners.org
617-855-2110
McLean Hospital
Source:Eurekalert

Related biology news :

1. UNCs Dr. Sean McLean receives Robert Wood Johnson Foundation award
2. Vitamin C rapidly improves emotional state of acutely hospitalized patients, say LDI researchers
3. Opioid use to relieve pain and suffering at end of life is safe in hospital-at-home setting
4. Researchers at Childrens Hospital Los Angeles find diet-induced obesity accelerates leukemia
5. Memorial Hospital Selects DigitalPersona Pro to Enhance HIPAA Security
6. Texas Childrens Hospital vaccine experts present 4 studies
7. Nude-colored hospital gowns could help doctors better detect hard-to-see symptoms
8. Temple University Hospital and PASNAP Negotiations Break Off: Talks to Resume Later Today
9. Researchers find Clostridium difficile is more common than MRSA in southeast community hospitals
10. Hospital scanner could curb nuclear waste threat
11. University Hospitals Case Medical Center testing gene therapy for Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... -- Atrius Health and IBM (NYSE: IBM ) ... develop a cloud based service designed to improve ... of the multiple influences on an individual,s health, ... designed to support shared decision making between physicians ... healthcare organization with 875 physicians caring for 675,000 ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... provides separate comprehensive analytics for the US, Japan ... estimates and forecasts are provided for the period 2015 through 2022. ... data and analytics are derived from primary and secondary research. This ...
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
Breaking Biology Technology: